Aytu BioPharma Inc (AYTU) surpasses revenue expectations with robust ADHD sales and prepares for the promising launch of Exua amidst strategic realignments.

BioStem Technologies Inc (BSEM) reports robust product volume growth and strategic market expansions, despite facing revenue and margin pressures.